Necitumumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types.

**Synonyms:** - Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8 - IMC 11F8 - IMC-11F8 - IMC11F8 - Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor (Receptor Tyrosine-Protein Kinase ErbB-1, EC 2.7.10.1)); Human Monoclonal IMC-11F8 Gamma1 Heavy Chain (224-214')-Disulfide with Human Monoclonal IMC-11F8 Kappa Light Chain, Dimer (230- 230'':233-233'')-Bisdisulfide - NECITUMUMAB - Portrazza